Literature DB >> 27366996

Innate immunity against hepatitis C virus.

Yongfen Xu1, Jin Zhong2.   

Abstract

Hepatitis C virus (HCV) infection tends persistent and causes chronic liver diseases, including inflammation, cirrhosis and hepatocellular carcinoma. Innate immune responses triggered by HCV infection, particularly the production of interferons and pro-inflammatory cytokines, shape the early host antiviral defense, and orchestrate subsequent HCV-specific adaptive immunity. Host has evolved multifaceted means to sense HCV infection to induce innate immune responses, whereas HCV has also developed elaborate strategies to evade immune attack. Recent studies in the field have provided many new insights into the interplay of HCV and innate immunity. In this review, we summarized these recent advances, focusing on pathogen recognition by innate sensors, newly discovered anti-HCV innate effectors and new viral strategies to evade innate immunity.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27366996     DOI: 10.1016/j.coi.2016.06.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  10 in total

1.  NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2.

Authors:  Yuwen Qin; Binbin Xue; Chunyan Liu; Xiaohong Wang; Renyun Tian; Qinya Xie; Mengmeng Guo; Guangdi Li; Darong Yang; Haizhen Zhu
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

2.  Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

Authors:  Yanan Zhao; Xuezhi Cao; Mingzhe Guo; Xuesong Wang; Tao Yu; Liqing Ye; Lin Han; Lei Hei; Wanyin Tao; Yimin Tong; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 3.  Taming a beast: lessons from the domestication of hepatitis C virus.

Authors:  Joseph M Luna; Mohsan Saeed; Charles M Rice
Journal:  Curr Opin Virol       Date:  2019-03-12       Impact factor: 7.090

4.  Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.

Authors:  Andri Vasou; Christina Paulus; Janina Narloch; Zoe O Gage; Marie-Anne Rameix-Welti; Jean-François Eléouët; Michael Nevels; Richard E Randall; Catherine S Adamson
Journal:  Antiviral Res       Date:  2017-10-14       Impact factor: 5.970

5.  Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway.

Authors:  Yisha Liang; Xuezhi Cao; Qiang Ding; Yanan Zhao; Zhenliang He; Jin Zhong
Journal:  PLoS Pathog       Date:  2018-05-21       Impact factor: 6.823

6.  Cytokine storms are primarily responsible for the rapid death of ducklings infected with duck hepatitis A virus type 1.

Authors:  Jinyan Xie; Mingshu Wang; Anchun Cheng; Xin-Xin Zhao; Mafeng Liu; Dekang Zhu; Shun Chen; Renyong Jia; Qiao Yang; Ying Wu; Shaqiu Zhang; Yunya Liu; Yanling Yu; Ling Zhang; Kunfeng Sun; Xiaoyue Chen
Journal:  Sci Rep       Date:  2018-04-26       Impact factor: 4.379

7.  Transcription Factor MafB Suppresses Type I Interferon Production by CD14+ Monocytes in Patients With Chronic Hepatitis C.

Authors:  Tie-Mei Liu; Han Wang; Dong-Na Zhang; Guang-Ze Zhu
Journal:  Front Microbiol       Date:  2019-08-07       Impact factor: 5.640

Review 8.  Hepatitis C Virus Vaccine: Challenges and Prospects.

Authors:  Joshua D Duncan; Richard A Urbanowicz; Alexander W Tarr; Jonathan K Ball
Journal:  Vaccines (Basel)       Date:  2020-02-17

9.  miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection.

Authors:  Yun Zhou; Peixin Zhang; Xuyang Zheng; Chuantao Ye; Mengyuan Li; Peiyu Bian; Chao Fan; Ying Zhang
Journal:  Ann Transl Med       Date:  2021-11

Review 10.  A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis.

Authors:  Corey Saraceni; John Birk
Journal:  J Clin Transl Hepatol       Date:  2021-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.